Sex: A major predictor of remission in early rheumatoid arthritis?

Annals of the Rheumatic Diseases

Volumn 66, Issue 1, 2007, Pages 46-52

  Forslind, K ^b   Hafstrom I ^c   Ahlmen M ^d   Svensson, Björn ^a,e  

^a Helsingborgs Lasarett ^*  (Sweden)

^b HELSINGBORG HOSPITAL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; RHEUMATOID FACTOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; SEX DIFFERENCE;

EID: 33846019964     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.056937     Document Type: Article

References (35)

1. EULAR handbook of clinical assessments in rheumatoid arthritis. The Netherlands: van Zuiden Communications BV 2000.
2. Prevoo ML, van Gestel AM, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the Disease Activity Score. Br J Rheumatol 1996;35:1101-5.
3. Pinals RS, Masi AT, Larsen RA, and the subcommittee for criteria of remission in rheumatoid arthritis of the American Rheumatism Association diagnostic and therapeutic criteria committee. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981;24:1308- 15.
4. Svensson B, Schaufelberger C, Teleman A, Theander J. Remission and response to early treatment of RA assessed by the Disease Activity Score. Rheumatology 2000;39:1031-6.
5. Balsa A, Carmona L, Gonzales-Alvaro I, Belmonte MA, Tena X, Sanmarti R for the EMECAR Study Group. Value of Disease Activity Score 28 (DAS28) and DAS28-3 compared to American College of Rheumatology-defined remission in rheumatoid arthritis. J Rheumatol 2004;31:40-6.
6. Ollier WER, Harrison B, Symmons D. What is the natural history of rheumatoid arthritis? Best Pract Res Clin Rheumatol 2001;15:27-48.
7. Sherrer YS, Bloch DA, Mitchell DM, Roth SH, Wolfe F, Fries JF. Disability in rheumatoid arthritis: comparison of prognostic factors across three populations. J Rheumatol 1987;14:705-9.
8. Furst DE. Predictors of worsening clinical variables and outcomes in rheumatoid arthritis. Rheum Dis Clin North Am 1994;2:309-19.
9. Katz PP, Criswell LA. Differences in symptom reports between men and women with rheumatoid arthritis. Arthritis Care Res 1996;6:441-8.
10. Kuiper S, van Gestel AM, Swinkels HL, de Boo TM, da Silva JA, van Riel PL. Influence of sex, age, and menopausal state on the course of early rheumatoid arthritis. J Rheumatol 2001;8:1809-16.
11. Odegard S, Finset A, Kvien TK, Mowinckel P, Uhlig T. Work disability in rheumatoid arthritis is predicted by physical and psychological health status: a 7-year study from the Oslo RA register. Scand J Rheumatol 2005;6:441-7.
12. Svensson B, Ahlmén M, Forslind K for the BARFOT Study Group. Treatment of early RA in clinical practice: a comparative study of two different DMARD/corticosteroid options. Clin Exp Rheumatol 2003;21:327-32.
13. Arnett FC, Edworthy SM, Bloch DAS28, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
14. Prevoo MLL, van't Hof NAA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
15. Van Gestel AM, Haagsma CJ, van Riel PLCM. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998;41:1845-50.
16. Eberhardt K, Svensson B, Moritz U. Functional assessment in early rheumatoid arthritis. Br J Rheumatol 1988;27:364-71.
17. Ekdahl C, Eberhardt K, Andersson SI, Svensson B. Assessing disability in patients with rheumatoid arthritis. Scand J Rheumatol 1988;17:263-71.
18. Scott DL. Prognostic factors in early rheumatoid arthritis. Rheumatology 2000;39(Suppl 1):124-9.
19. Harrison B, Symmons D. Early inflammatory polyarthritis: results from the Norfolk Arthritis Register with a review of the literature. II Outcome at three years. Rheumatology 2000;39:939-49.
20. Mäkinen H, Kautiainen H, Hannonen P, Sokka T. Frequency of remissions in early rheumatoid arthritis defined by 3 sets of criteria. A 5-year followup study. J Rheumatol 2005;32:796-800.
21. Fransen J, Creemers MCW, van Riel PLCM. Remission in rheumatoid arthritis: agreement of the Disease Activity Score (DAS28) with the ARA preliminary remission criteria. Rheumatology 2004;43:1252-5.
22. Mäkinen H, Kautiainen H, Hannonen P, Sokka T. Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? Ann Rheum Dis 2005;64:1410-13.
23. Landewe RB, van der Heijde DM, van der Linden S, Boers M. 28-joint counts invalidate the DAS28-remission definition due to the omission of the lower extremity joints: a comparison with the original DAS-remission. Ann Rheum Dis 2006;65:637-41.
24. Svensson B, Boonen A, Albertsson K, van der Heijde D, Keller C, Hafström I, for the BARFOT Study Group. Low dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases remission rate: a two-year randomised trial. Arthritis Rheum 2005;52:3360- 70.
25. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
26. Landewe RBM, Boers M, Verhoeven AC, Westhovens R, van de Laar MA, Markusse HM, et al. COBRA combination therapy in patients with early rheumatoid arthritis. Long-term structural benefits of a brief intervention. Arthritis Rheum 2002;46:347-56.
27. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. for the active-controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset study group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis. A randomized controlled trial. Arthritis Rneum 2004;50:3432-43.
28. Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal. Results from a twelve-month randomized double-blind placebo-controlled trial. Arthritis Rheum 2005;52:27-35.
29. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. for the TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial, Lancet 2004;363:675-81.
30. Van der Heijde D, Klareskog L, Boers M, Landewe R, Codreanu C, Bolosiu HD, et al. for the TEMPO investigators. Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results, Ann Rheum Dis 2005;64:1582-7.
31. Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Chartash EK, Segurado OG. Long-term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis 2006;65:753-9.
32. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-9.
33. Gossec L, Dougados M, Goupille P, Cantagrel A, Sibilia J, Meyer O, et al. Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. Ann Rheum Dis 2004;63:675-80.
34. Möttönen T, Paimela L, Leirisalo-Repo M, Kautiainen H, Ilonen J, Hannonen P. Only high disease activity and positive rheumatoid factor indicate poor prognosis in patients with early rheumatoid arthritis treated with "sawtooth" strategy. Ann Rheum Dis 1998;57:533-9.
35. Tengstrand B, Ahlmén M, Hafström I, for the BARFOT Study Group. The influence of gender on rheumatoid arthritis: a prospective study of onset and outcome after 2 years. J Rheumatol 2004;31:214-22.